Across Richmond, lawmakers are losing patience as federal reform efforts tied to the 340B program continue to stall. The initiative helps select hospitals and clinics secure discounted drugs, but allegations of misuse have shadowed it for a long time.
Originally, Senate Bill 278 aimed to push back against restrictions from pharmaceutical companies. Over time, it changed direction and now proposes forming a state workgroup. “We can’t assume that the feds are going to do anything productive,” Del. Cia Price said, echoing broader frustration.
The 340B program gives certain hospitals and clinics that treat low-income patients the ability to buy prescription drugs at deep discounts. They can charge insurers the usual rates and keep the difference, using that money to fund care for underserved communities.
For many providers, those savings are not extra, they are essential. “Without 340B, we would not exist,” said Stacie Walls of Norfolk’s LGBT Life Center, explaining that the program helps sustain in-house pharmacies and critical HIV services across Hampton Roads.
Concerns grew as large hospital systems increased participation after eligibility expanded under the Affordable Care Act in 2010. A 2022 New York Times investigation reported that Bon Secours redirected resources, leading Dr. Lucas English to argue profits were placed ahead of patients.
Senate Bill 278 first aimed to stop pharmaceutical companies registered in Virginia from limiting how many contract pharmacies could receive 340B drugs. Supporters described it as a straightforward answer to restrictions they believe have placed added strain on clinics serving vulnerable patients.
As amended, the proposal now calls for a state workgroup to examine how 340B operates within Virginia. Del. Keith Hodges said, “Right now, we need to try to address it at the state level,” backing a study over immediate mandates.
Not everyone welcomed the change. Virginia Community Healthcare Association CEO Tracy Douglas said, “Our patients needed that bill and now we have a study,” arguing safety-net providers continue to absorb pressure while larger players debate policy.
Since 2023, a congressional workgroup in Washington has been studying 340B and exploring ways to adjust it. U.S. Sen. Tim Kaine said lawmakers aim to manage growth and curb misuse, though no draft proposal has been formally introduced.
Meanwhile, President Donald Trump’s administration suggested converting 340B into a rebate-based system. Kaine questioned whether smaller clinics could realistically pay full price first and wait for reimbursement without reliable cash flow.
A federal judge stepped in last month and blocked the pilot plan, preventing quick changes. Industry representatives, including PhRMA, continue to call the program flawed, saying stronger transparency measures could support patients and reinforce long-term stability.
The bill has cleared the Senate and now moves through the House, where lawmakers must decide whether a study is enough. If approved, it will land on Gov. Abigail Spanberger’s desk, placing the final call on Virginia’s next step.
Behind the policy debate are clinics, hospitals, and drugmakers pulling in different directions. As Tracy Douglas warned, patients often get caught in the crossfire. What happens next could shape how safety-net providers survive and how oversight is defined statewide.